中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 自动化研究所
  3. 中国科学院自动化研究所
  4. 中国科学院分子影像重点实验室
Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging

文献类型：期刊论文

作者Liu, Shengnan1,2; Du, Yang2,3,4; Ma, He1; Liang, Qian2,3,4; Zhu, Xu5; Tian, Jie2,3,4,6,7
刊名CANCER LETTERS
出版日期2019
卷号453页码:74-83
关键词Hepatocellular carcinoma Regorafenib Sorafenib Molecular imaging Therapeutic effects
ISSN号0304-3835
DOI10.1016/j.canlet.2019.03.037
通讯作者Ma, He(mahe@bmie.neu.edu.cn) ; Zhu, Xu(drzhuxu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn)
英文摘要Sorafenib has been used as a clinical targeted therapy for hepatocellular carcinoma (HCC) for more than a decade. In 2017, regorafenib was approved for HCC treatment and has since been reported to prolong the survival of advanced HCC patients after treatment failure with sorafenib. However, there has been no direct systematic comparison of the therapeutic effects of regorafenib and sorafenib against HCC. In this study, we comprehensively compared the therapeutic effects of sorafenib and regorafenib against HCC in vitro and in vivo using multimodality molecular imaging, which can show molecular and cellular differences at early stages. The side effects of sorafenib and regorafenib were also systematically evaluated. The data showed that compared with sorafenib treatment, regorafenib exerted stronger antitumor and antiangiogenic effects and significantly increased the survival rate of HCC mice. Sorafenib but not regorafenib treatment caused body weight loss and liver and kidney dysfunction, while regorafenib but not sorafenib treatment caused hypertension. Our study may provide an experimental basis for the guidance of clinical HCC targeted treatment with regorafenib and sorafenib.
WOS关键词BAY 73-4506 ; APOPTOSIS ; THERAPY ; CANCER ; TUMOR
资助项目National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022]
WOS研究方向Oncology
语种英语
WOS记录号WOS:000467511100007
出版者ELSEVIER IRELAND LTD
资助机构National Key Research and Development Plan of China ; National Natural Science Foundation of China ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science and Technology Commission
源URL[http://ir.ia.ac.cn/handle/173211/24585]  
专题自动化研究所_中国科学院分子影像重点实验室
通讯作者Ma, He; Zhu, Xu; Tian, Jie
作者单位1.Northeastern Univ, Sinodutch Biomed & Informat Engn Sch, Shenyang, Liaoning, Peoples R China
2.Chinese Acad Sci, Inst Automat, State Key Lab Management & Control Complex Syst, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
3.Beijing Key Lab Mol Imaging, Beijing 100190, Peoples R China
4.Univ Chinese Acad Sci, Beijing 100080, Peoples R China
5.Peking Univ, Sch Oncol, Key Lab Carcinogenesis & Translat Res, Dept Intervent Therapy,Minist Educ Beijing, 52 Fucheng Rd, Beijing 100142, Peoples R China
6.Beihang Univ, Sch Med, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100191, Peoples R China
7.Xidian Univ, Sch Life Sci & Technol, Minist Educ, Engn Res Ctr Mol & Neuro Imaging, Xian 710126, Shaanxi, Peoples R China
推荐引用方式
GB/T 7714		 Liu, Shengnan,Du, Yang,Ma, He,et al. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging[J]. CANCER LETTERS,2019,453:74-83.
APA Liu, Shengnan,Du, Yang,Ma, He,Liang, Qian,Zhu, Xu,&Tian, Jie.(2019).Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.CANCER LETTERS,453,74-83.
MLA Liu, Shengnan,et al."Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging".CANCER LETTERS 453(2019):74-83.

入库方式： OAI收割

来源：自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。